Stelrad Group (SRAD) Competitors

Dr. Martens (LON:DOCS) and Stelrad Group (LON:SRAD) are both small-cap computer software companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Which has preferable valuation and earnings, DOCS or SRAD?

Dr. Martens has higher revenue and earnings than Stelrad Group. Stelrad Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Martens	£787.60M	1.13	£68.97M	£0.01	18,400.00
Stelrad Group	£283.94M	0.73	£16.13M	£0.04	4,179.49

Does the media favor DOCS or SRAD?

In the previous week, Dr. Martens had 1 more articles in the media than Stelrad Group. MarketBeat recorded 4 mentions for Dr. Martens and 3 mentions for Stelrad Group. Stelrad Group's average media sentiment score of 0.20 beat Dr. Martens' score of 0.18 indicating that Stelrad Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Martens	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stelrad Group	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals have more ownership in DOCS or SRAD?

32.1% of Dr. Martens shares are owned by institutional investors. Comparatively, 16.8% of Stelrad Group shares are owned by institutional investors. 2.8% of Dr. Martens shares are owned by company insiders. Comparatively, 15.6% of Stelrad Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is DOCS or SRAD a better dividend stock?

Dr. Martens pays an annual dividend of GBX 0.02 per share and has a dividend yield of 0.0%. Stelrad Group pays an annual dividend of GBX 0.08 per share and has a dividend yield of 0.0%. Dr. Martens pays out 368.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Stelrad Group pays out 199.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Stelrad Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do analysts recommend DOCS or SRAD?

Dr. Martens presently has a consensus price target of GBX 6,000, indicating a potential upside of 6,421.74%. Stelrad Group has a consensus price target of GBX 200, indicating a potential upside of 22.70%. Given Dr. Martens' higher possible upside, equities research analysts clearly believe Dr. Martens is more favorable than Stelrad Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Stelrad Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, DOCS or SRAD?

Dr. Martens has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Stelrad Group has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500.

Is DOCS or SRAD more profitable?

Dr. Martens has a net margin of 7.89% compared to Stelrad Group's net margin of 5.25%. Stelrad Group's return on equity of 28.08% beat Dr. Martens' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Martens	7.89%	18.91%	8.12%
Stelrad Group	5.25%	28.08%	7.46%

Summary

Dr. Martens beats Stelrad Group on 9 of the 17 factors compared between the two stocks.